RxDoctor Payments DataLook up a doctor →

Clint Kingsley, MD

Hematology & Oncology · Florence, ALNPI 1053348037

Payments from drug & device makers

$791,791in general payments, 2019–2025

Across 701 payments — averaging $1129.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$459K
  • Merck$143K
  • Eli Lilly$101K
  • E.r. Squibb & Sons, L.L.C.$75K
  • Novartis$4K
  • AstraZeneca$1K
  • plus $8K from 54 others
$3,599in research payments, 2019–2025

Across 3 payments — averaging $1199.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$4K

What the payments were for

  • Speaking & faculty fees$1201%
  • Food & beverage$11,61597%
  • Education$2342%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.24$459,405
Merck84$142,614
Eli Lilly5$101,168
E.r. Squibb & Sons, L.L.C.35$75,000
Novartis74$4,190
AstraZeneca(2 entities)51$1,113
Johnson & Johnson33$693
Pfizer31$599
Seagen Inc.30$505
Incyte Corporation22$479
Genentech USA, Inc.20$358
Exelixis Inc.13$302
AbbVie16$289
Takeda Pharmaceuticals U.S.A., Inc.12$286
Sanofi13$279
Bristol Myers Squibb13$278
Gilead(2 entities)15$253
Pharmacyclics LLC, An Abbvie Company12$219
Regeneron Healthcare Solutions, Inc.8$216
Eisai Inc.10$206
Daiichi Sankyo Inc.11$204
Amgen14$200
Lilly USA, LLC13$194
Bayer10$194
Beone Medicines USA, Inc.10$186
Beigene USA, Inc.8$141
Stemline Therapeutics Inc.6$140
Astellas Pharma US Inc5$132
Tersera Therapeutics LLC6$126
Array Biopharma Inc7$120
Ipsen Biopharmaceuticals, Inc5$113
Boehringer Ingelheim4$94
Sobi, Inc5$92
Blueprint Medicines Corporation4$89
AVEO Pharmaceuticals, Inc.5$82
Pharmaessentia USA Corporation4$81
Springworks Therapeutics, Inc.3$77
Servier Pharmaceuticals LLC4$76
ADC Therapeutics America, Inc.4$72
GSK4$70
Coherus Oncology, Inc.3$67
Rigel Pharmaceuticals, Inc.4$61
Mirati Therapeutics, Inc.4$61
Sumitomo Pharma America, Inc.3$55
Deciphera Pharmaceuticals Inc.2$51
Puma Biotechnology, Inc.3$51
Karyopharm Therapeutics Inc.3$51
Adaptive Biotechnologies Corporation3$47
Iovance Biotherapeutics, Inc.3$46
Kyowa Kirin, Inc.2$41
Geron Corporation2$41
Recordati_rare_diseases_inc.2$38
Agios Pharmaceuticals, Inc.2$36
Genmab U.S., Inc.2$36
Dendreon Pharmaceuticals LLC1$25
Jazz Pharmaceuticals Inc.1$23
Shield Therapeutics Inc1$20
Novocure Inc.1$19
Global Blood Therapeutics, Inc.1$17
Acrotech Biopharma Inc.1$17

How this compares

$791,791 in reported general payments places this provider in the 85th percentile of 177 hematology & oncology providers in Alabama.

See all hematology & oncology providers in Alabama

Medicare billing

Part B allowed, 2024
$6,817,317
Medicare patients
988
Services billed
229,910

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PromactaEltrombopag Olamine44$783,371
XtandiEnzalutamide49$690,711
JakafiRuxolitinib Phosphate52$687,339
TasignaNilotinib Hcl28$514,832
PomalystPomalidomide14$329,401
LenvimaLenvatinib Mesylate13$303,493
RevlimidLenalidomide16$287,322
BrukinsaZanubrutinib21$279,812
KisqaliRibociclib Succinate18$277,089
Lenalidomide16$237,483
IbrancePalbociclib14$197,888
VerzenioAbemaciclib15$183,481
ImbruvicaIbrutinib11$174,774
NubeqaDarolutamide11$152,302
ErivedgeVismodegib11$142,236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisPromacta, Tasigna, Kisqali$4,190$1,575,29290 claims
Astellas Pharma US IncXtandi$132$690,71149 claims
Incyte CorporationJakafi$479$687,33952 claims
PfizerIbrance, Trazimera, Eliquis$599$329,813102 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$75,000$329,40114 claims
Eisai Inc.Lenvima$206$303,49313 claims
Bristol Myers SquibbRevlimid$278$287,32216 claims
Beigene USA, Inc.Brukinsa$141$279,81221 claims
Lilly USA, LLCVerzenio$194$183,48115 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$219$174,77411 claims
BayerNubeqa$194$152,30211 claims
Genentech USA, Inc.Erivedge$358$142,23611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 177 hematology & oncology providers in Alabama.

Other hematology & oncology in Florence

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →